Abstract:Abstract Pyruvate kinase M2 (PKM2) has been shown to promote tumorigenesis by facilitating the Warburg effect and enhancing the activities of oncoproteins. However, this paradigm has recently been challenged by studies in which the absence of PKM2 failed to inhibit and instead accelerated tumorigenesis in mouse models. These results seem inconsistent with the fact that most human tumors overexpress PKM2. To further elucidate the role of PKM2 in tumorigenesis, we investigated the effect of PKM2 knockout in oncogenic HRAS-driven urothelial carcinoma. While PKM2 ablation in mouse urothelial cells did not affect tumor initiation, it impaired the growth and maintenance of HRAS-driven tumors. Chemical inhibition of PKM2 recapitulated these effects. Both conditions substantially reduced complex formation of PKM2 with STAT3, their nuclear translocation, and HIF1α- and VEGF-related angiogenesis. The reduction in nuclear STAT3 in the absence of PKM2 also correlated with decreased autophagy and increased apoptosis. Time-controlled, inducible PKM2 overexpression in simple urothelial hyperplasia did not trigger tumorigenesis, while overexpression of PKM2, but not PKM1, in nodular urothelial hyperplasia with angiogenesis strongly accelerated tumorigenesis. Finally, in human patients, PKM2 was overexpressed in low-grade nonmuscle-invasive and high-grade muscle-invasive bladder cancer. Based on these data, PKM2 is not required for tumor initiation but is essential for tumor growth and maintenance by enhancing angiogenesis and metabolic addiction. The PKM2–STAT3–HIF1α/VEGF signaling axis may play a critical role in bladder cancer and may serve as an actionable therapeutic target. Significance: Genetic manipulation and pharmacologic inhibition of PKM2 in mouse urothelial lesions highlight its essential role in promoting angiogenesis and metabolic addiction, events indispensable for tumor growth and maintenance.

PKM2 promotes glioma progression by mediating CTNNB1 expression

PSMC2/E2F1 Axis Promotes the Development and Progression of Glioma

PKM2 Regulates Chromosome Segregation and Mitosis Progression of Tumor Cells.

PKM2 Upregulation Promotes Malignancy and Indicates Poor Prognosis for Intrahepatic Cholangiocarcinoma.

Expression, functions and regulation of PKM2 in tumor cells

PKM2 Drives Hepatocellular Carcinoma Progression by Inducing Immunosuppressive Microenvironment

PKM2 regulates neural invasion of and predicts poor prognosis for human hilar cholangiocarcinoma

Pyruvate Kinase Type M2 is Upregulated in Colorectal Cancer and Promotes Proliferation and Migration of Colon Cancer Cells.

Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics

PKM2 Promotes Metastasis by Recruiting Myeloid-Derived Suppressor Cells and Indicates Poor Prognosis for Hepatocellular Carcinoma.

PKM2 promotes tumor angiogenesis by regulating HIF-1α through NF-κB activation

The role of PKM2 in cancer progression and its structural and biological basis

PKC signaling in glioblastoma

Pyruvate Kinase M2 Contributes to Cell Growth in Gastric Cancer Via Aerobic Glycolysis.

EGFR-Induced and PKCε Monoubiquitylation-Dependent NF-κB Activation Upregulates PKM2 Expression and Promotes Tumorigenesis

PKM2 Dephosphorylation by Cdc25A Promotes the Warburg Effect and Tumorigenesis

PKM2 regulates hepatocellular carcinoma cell epithelial-mesenchymal transition and migration upon EGFR activation.

The ratio of PKM1/PKM2 is the key factor affecting the glucose metabolism and biological function of colorectal cancer cells

PKM2 Phosphorylates Histone H3 and Promotes Gene Transcription and Tumorigenesis

PKM2 Is Essential for Bladder Cancer Growth and Maintenance

Nuclear PKM2 Regulates the Warburg Effect.